{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.70","upperLimit":"80.40","value":"15.60"},{"groupId":"OG001","lowerLimit":"0.65","upperLimit":"107.00","value":"22.35"}]}],"title":"Week 12: Follow-up Visit 1 (n = 117, 118)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.58","upperLimit":"17.40","value":"2.89"},{"groupId":"OG001","lowerLimit":"0.69","upperLimit":"62.10","value":"5.19"}]}],"title":"Week 24: Follow-up Visit 2 (n = 88, 96)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.52","upperLimit":"51.40","value":"1.08"},{"groupId":"OG001","lowerLimit":"0.53","upperLimit":"33.90","value":"2.02"}]}],"title":"Week 36: Follow-up Visit 3 (n = 38, 53)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Eight cycles of rituximab IV infusion (375 mg/m\\^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\\^2) once every 8 weeks for 24 months.","id":"OG000","title":"Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)"},{"description":"First cycle rituximab IV infusion (375 mg/m\\^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.","id":"OG001","title":"Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)"}],"paramType":"MEDIAN","populationDescription":"Safety Analysis Population included all participants who received at least one dose of rituximab, either IV or SC. Participants were analyzed as treated. Here, number of participants analyzed = participants evaluable for the outcome measure. Here \"n\" = number of participants evaluable for this outcome measure at specified timepoint.","reportingStatus":"POSTED","timeFrame":"12 weeks, 24 weeks, and 36 weeks after the last rituximab administration (up to data cutoff of 11 Jan 2016 [up to 6 years])","title":"Stage I and II (Pooled): Rituximab Levels 12 Weeks, 24 Weeks, and 36 Weeks After the Last Rituximab Administration","type":"SECONDARY","unitOfMeasure":"mcg/mL"}